OBJECTIVE: MicroRNAs (miRs) are small single-stranded, non-coding RNAs, which function to alter gene transcription in cell function and are important biomarker molecules of cardiac morphogenesis, cardiomyocyte growth, and differentiation. The goal of this study is to establish a normal miR expression profile in serum of pregnant women at risk of having fetuses with CHDs. STUDY DESIGN: Venous maternal blood samples were prospectively collected from pregnancies at risk for CHD (nuchal translucency thickness >3 mm, reversed ductus venosus a-wave, tricuspid regurgitation, pregestational diabetes, anticonvulsant use, or history of cardiac defects) following an echocardiogram in each trimester. Fetuses with fetal structural abnormalities and chromosomal anomalies (pre-or post-natal diagnosed) were excluded. Serum RNA was extracted and 797 human miRs were quantified using NanoString nCounter technology as counts (molecules/100ngRNA). miR expression counts were considered low if counts ranged between 20-80, just above the median count value of 20. miR expression profiles of each trimester were analyzed from different patients in 1 st (N¼46), 2 nd (N¼6), and 3 rd (N¼6) trimesters. RESULTS: The majority of miRs exhibited low expression of 26%, 47%, and 55% of the total miR profile in each of the trimesters, respectively. Of these, miR expression increased in the 2 nd compared to the 1 st trimester but variably changed (increased, decreased, no change) in the 3 rd compared to the 2 nd trimester (Fig 1) . There was a broad range of expression 361) in each trimester with an average maximum count of 7,423 (1 st ), 32,261 (2 nd ), and 17,829 (3 rd ). Of the known placentally-derived miRs (n¼114), all exhibited a low expression level (20-80 units) (Fig 2) . CONCLUSION: This study identifies the magnitude, variance, and temporal changes in miR expression during the course of pregnancy and will be important in future studies for generating a select biomarker miRs profile for early detection of fetal CHDs.
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Poster Session I OBJECTIVE: Ventricular septal defects (VSD) account for 20% of congenital heart defects (CHDs) and the pathogenesis and molecular mechanism have not been elucidated. MicroRNAs (miRs) are small single-stranded, non-coding RNA molecules that regulate gene expression at the post-transcriptional level. Recent research demonstrated that miRs help regulate embryonic cardiac development, cardiac mophogenesis, and cardiomyocyte growth and differentiation and are closely related to the occurrence of CHDs. This study aimed to measure differences in miR expression in maternal serum in patients complicated with fetal muscular VSD. STUDY DESIGN: This was a prospective study including fetuses at risk for CHD (pregestational diabetes, anticonvulsant use, or history of cardiac defects) during 2 nd trimester echocardiographic examination. Fetuses without cardiac abnormalities were marked as control. Fetuses with isolated mVSD were marked as abnormal. Maternal venous serum was collected, RNA extracted, and an expression profile of 797 human miRs was measured using NanoString nCounter technology as counts (molecules/100ng RNA). Expression levels of >2fold increase or <50% decrease compared to control were considered up-or downregulated, respectively. Placentalderived miRs within the entire expression profile were also evaluated separately. RESULTS: miRs profiling was obtained in 6 controls and 7 mVSDs cases. Expression levels ranged from 3-198 counts, indicating relatively low expression. The median count did not vary between normal (20.7) and mVSD (21.4). Of the 797, 12 miRs were significantly upregulated (Fig. 1) and 36 miRs downregulated (P<0.01 for both). There were no differences in expression among the 114 known placentally-derived miRs between groups. CONCLUSION: This study identifies a select serum miR expression profile in women with mVSD fetuses in the 2 nd trimester that differs from women with normal fetuses. This approach may provide a quantitative screening tool for confirming fetal CHDs diagnosed by echocardiography. This will be valuable as a biomarker approach for early detection of fetal CHDs in the first trimester to aid diagnosis by fetal echocardiography. .
237 Maternal HDL in early pregnancy as a risk factor for small-for-gestational-age birthweight OBJECTIVE: The pathophysiology of uteroplacental insufficiency is not well understood. One mechanism that has been proposed includes atherosclerosis of basal arterioles and diffuse lipid infiltration of the placental bed leading to an obstructive vasculopathy. Highdensity lipoprotein cholesterol (HDL) is protective against atherosclerosis in adults, but the effect of maternal serum HDL levels on fetal growth is not well determined. We evaluated the relationship between maternal HDL in the first trimester and subsequent risk for small-for-gestational-age birthweight (SGA). STUDY DESIGN: This is a secondary analysis of a prospective cohort study of healthy Korean women with singleton pregnancies designed to examine the risk of gestational diabetes mellitus (GDM) in the setting of nonalcoholic fatty liver disease (NAFLD) diagnosed by ultrasound. Maternal fasting blood was taken at 10-14 weeks' gestation and lipid parameters measured. SGA was defined as birthweight <10th percentile for gestational age. RESULTS: Among 937 women enrolled, 898 (95.8%) delivered at term. Of these, 73 (8.1%) were SGA and 825 (91.9%) were not. Maternal HDL levels at 10-14 weeks were significantly lower in women who delivered SGA neonates than those who did not (p¼0.004), and the risk for SGA was significantly negative correlated
